RAPIVAB
Biological
BioCryst Pharmaceuticals, Inc.
Total Payments
$21,911
Transactions
546
Doctors
480
Companies
2
Payment Trends by Year
| Year | Amount | Transactions | Doctors |
|---|---|---|---|
| 2022 | $13,200 | 1 | 0 |
| 2017 | $8,711 | 545 | 480 |
Payments by Nature
| Nature of Payment | Amount | Transactions | Share |
|---|---|---|---|
| Unspecified | $13,200 | 1 | 60.2% |
| Food and Beverage | $8,711 | 545 | 39.8% |
Payments by Type
Research
$13,200
1 transactions
General
$8,711
545 transactions
Research Studies & Clinical Trials
| Study Name | Sponsor | Amount | Doctors |
|---|---|---|---|
| A Phase 3, single-arm, open-label study to evaluate the safety and pharmacokinetics of intravenous peramivir in pediatric subjects from birth to 6 months of age infected with influenza A or B | BioCryst Pharmaceuticals, Inc. | $13,200 | 0 |
Top Doctors Receiving Payments for RAPIVAB — Page 5
| Doctor | Specialty | Location | Total | Records |
|---|---|---|---|---|
| , MD | Pulmonary Disease | Decatur, GA | $21.48 | 1 |
| , M.D | Critical Care Medicine | Decatur, GA | $21.47 | 1 |
| , M.D | Critical Care Medicine | Fairfax, VA | $21.33 | 1 |
| , M.D | Pulmonary Disease | St. Charles, MO | $21.23 | 1 |
| , MD | Infectious Disease | Bryn Mawr, PA | $21.19 | 1 |
| , M.D | Infectious Disease | Bryn Mawr, PA | $21.19 | 1 |
| , MD | Infectious Disease | Bryn Mawr, PA | $21.19 | 1 |
| , M.D | Hospitalist | Hattiesburg, MS | $20.94 | 1 |
| , M.D | Internal Medicine | Hattiesburg, MS | $20.94 | 1 |
| , M.D | Internal Medicine | Hattiesburg, MS | $20.93 | 1 |
| , MD | Hospitalist | Hattiesburg, MS | $20.93 | 1 |
| , MD | Pulmonary Disease | Plano, TX | $20.75 | 1 |
| , M.D | Hematology & Oncology | Jackson, MS | $20.70 | 1 |
| , M.D | Internal Medicine | Jackson, MS | $20.70 | 1 |
| , M.D | Infectious Disease | Lawrenceville, GA | $20.36 | 1 |
| , M.D | Infectious Disease | Atlanta, GA | $20.32 | 1 |
| , M.D | Infectious Disease | Atlanta, GA | $20.31 | 1 |
| , MD | Interventional Cardiology | Kansas City, MO | $20.23 | 1 |
| , MD | Hospitalist | Hattiesburg, MS | $20.13 | 1 |
| , MD | Hospitalist | Hattiesburg, MS | $20.13 | 1 |
| , MD | Hospitalist | Hattiesburg, MS | $20.13 | 1 |
| , M.D | Student in an Organized Health Care Education/Training Program | Hattiesburg, MS | $20.13 | 1 |
| , MD | Family Medicine | Saginaw, MI | $20.09 | 1 |
| , MD | Internal Medicine | Saginaw, MI | $20.08 | 1 |
| , MD | Internal Medicine | Saginaw, MI | $20.08 | 1 |
Ad
Manufacturing Companies
- BioCryst Pharmaceuticals, Inc. $13,200
- Seqirus USA Inc $8,711
Product Information
- Type Biological
- Total Payments $21,911
- Total Doctors 480
- Transactions 546
About RAPIVAB
RAPIVAB is a biological associated with $21,911 in payments to 480 healthcare providers, recorded across 546 transactions in the CMS Open Payments database. The primary manufacturer is BioCryst Pharmaceuticals, Inc..
Payment data is available from 2017 to 2022. In 2022, $13,200 was paid across 1 transactions to 0 doctors.
The most common payment nature for RAPIVAB is "Unspecified" ($13,200, 60.2% of total).
RAPIVAB is associated with 1 research study, including "A Phase 3, single-arm, open-label study to evaluate the safety and pharmacokinetics of intravenous peramivir in pediatric subjects from birth to 6 months of age infected with influenza A or B" ($13,200).